Hereditary Angioedema - Epidemiology Forecast - 2030

Hereditary Angioedema - Epidemiology Forecast - 2030

  • July 2020 •
  • 100 pages •
  • Report ID: 5921861 •
  • Format: PDF
‘Hereditary Angioedema (HAE)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hereditary Angioedema (HAE) Disease Understanding
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon.
The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum. The severity and timing of HAE attacks are unpredictable, mainly due to the lack of a complete understanding of the underlying mechanisms. Also, swelling without urticaria is the feature of most HAE attacks, regardless of the molecular basis.
HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.
Treatment of HAE has evolved with advancement in understanding the pathogenesis of this disease. It is directed towards either replacing the defective protein or blocking various molecules involved in the production of bradykinin or the bradykinin receptor.

<>Hereditary Angioedema (HAE) Epidemiology
The Hereditary Angioedema epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Hereditary Angioedema epidemiology segmented as the Total diagnosed Prevalent of Hereditary Angioedema, Gender-specific cases of Hereditary Angioedema, Age-specific cases of Hereditary Angioedema, Type-specific cases of Hereditary Angioedema, Site-specific cases of Hereditary Angioedema, the report includes the Prevalent scenario of Hereditary Angioedema symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

<>Country Wise- Hereditary Angioedema (HAE) Epidemiology
The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total diagnosed prevalent population of Hereditary Angioedema Associated in 7MM countries estimated to be 14,435 cases in 2017.
• As per the estimates, the United States has the highest prevalent population of Hereditary Angioedema with 6,566 cases in 2017.
• Among the EU5 countries, France had the highest prevalent population of 1,346 cases, followed by the UK.

Scope of the Report
• Hereditary Angioedema (HAE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• Hereditary Angioedema (HAE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Hereditary Angioedema (HAE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Hereditary Angioedema (HAE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Hereditary Angioedema
• The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
• The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Gender-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
• The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Age-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
• The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Type-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
• The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Site-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM

Report Highlights

<>• 11-Year Forecast of Hereditary Angioedema (HAE) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Hereditary Angioedema (HAE)
• Prevalent Cases according to segmentation: Gender-specific Prevalence of Hereditary Angioedema (HAE)
• Prevalent Cases according to segmentation: Age-specific Prevalence of Hereditary Angioedema (HAE)

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Hereditary Angioedema (HAE)?
• What are the key findings of the Hereditary Angioedema (HAE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Hereditary Angioedema (HAE) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Hereditary Angioedema?
• What are the currently available treatments of Hereditary Angioedema?

Reasons to buy
The Hereditary Angioedema (HAE) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Hereditary Angioedema (HAE) market
• Quantify patient populations in the global Hereditary Angioedema (HAE) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hereditary Angioedema (HAE) therapeutics in each of the markets covered
• Understand the magnitude of Hereditary Angioedema (HAE) population by its Prevalence cases
• Understand the magnitude of Hereditary Angioedema (HAE) population by its Gender-specific cases
• Understand the magnitude of Hereditary Angioedema (HAE) population by its Age-specific cases
• The Hereditary Angioedema (HAE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Hereditary Angioedema (HAE) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

<>• Patient Segmentation
• Disease Risk and Burden

<>• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
According to the US National Library of Medicine, Hereditary angioedema is estimated to affect 1 in 50,000 people; with the prevalence ranging from 1/10,000 to 1/150,000 of the general population. HAE-associated mortality due to the absence of treatment approaches is about 30% and results from laryngeal edema and asphyxiation predominantly (NIH, n.d.).